ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company's proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS has offices in Toronto, Ontario and Cambridge, Massachusetts.CAMBRIDGE, Massachusetts and TORONTO, Ontario, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that Neil Warma, interim Chief Executive Officer of ProMIS Neurosciences and Larry Altstiel, M.D., Ph.D., Chief Medical Officer of ProMIS Neurosciences, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 6, 2024 at 12:00 p.m. ET.
生物技術公司ProMIS Neurosciences Inc.（納斯達克代碼：PMN）專注於生成和開發針對神經退行性疾病中的有毒錯誤摺疊蛋白的治療藥物。今天宣佈，ProMIS Neurosciences的臨時首席執行官Neil Warma和ProMIS Neurosciences的首席醫療官Larry Altstiel萬.D.博士將在2024年8月6日下午12:00 ET參加BTIG虛擬生物技術會議的爐邊聊天。
A live webcast of the fireside chat will be available to conference participants.
現場網絡直播將向與會者提供。
About ProMIS Neurosciences Inc.
關於ProMIS Neurosciences Inc.
ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company's proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS has offices in Toronto, Ontario and Cambridge, Massachusetts.
ProMIS神經科學公司是一家臨床階段的生物技術公司，專注於生成和開發抗體治療，有選擇地針對神經變性疾病如阿爾茨海默病（AD）、肌萎縮性側索硬化（ALS）和多系統萎縮（MSA）中的有毒錯折蛋白質。該公司的專有目標發現引擎採用熱力學、計算發現平台- ProMIS和Collective Coordinates-在誤折的蛋白質的分子表面上預測新的目標，被稱爲特異性疾病表位。利用這種獨特的方法，該公司正在開發針對AD、ALS和MSA的新型抗體治療方法。ProMIS在安大略省的多倫多和馬薩諸塞州的劍橋設有辦事處。
For further information:
進一步了解：
Visit us at
請訪問我們的網址
Please submit media inquiries to info@promisneurosciences.com.
請將媒體查詢提交至info@promisneurosciences.com。
For Investor Relations, please contact:
Precision AQ
Anne Marie Fields, Managing Director
annemarie.fields@precisionaq.com
Tel. 212-362-1200
如需投資者關係，請聯繫：
Josh.Rappaport@precisionaq.com
Anne Marie Fields，董事總經理
annemarie.fields@precisionaq.com
電話：212-362-1200
譯文內容由第三人軟體翻譯。
